Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study.
Hepatic arterial infusion chemotherapy
Hepatocellular carcinoma
Lenvatinib
Portal vein tumor thrombosis
Radiation therapy
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
14
05
2021
accepted:
11
07
2021
pubmed:
23
7
2021
medline:
16
9
2021
entrez:
22
7
2021
Statut:
ppublish
Résumé
The overall survival of patients with advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar branches of the portal vein is extremely poor. Moreover, there is no standard treatment established for the condition. Herein, we present the case of a 65-year-old man who were treated the patient with hepatic arterial infusion chemotherapy, radiation therapy for tumor thrombosis, portal vein stent placement, lenvatinib administration, and renal venous shunt embolization. A complete response was observed according to mRECIST and the patient has been alive for 14 months since treatment initiation with no tumor recurrence.
Identifiants
pubmed: 34291386
doi: 10.1007/s12328-021-01481-9
pii: 10.1007/s12328-021-01481-9
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1517-1524Informations de copyright
© 2021. Japanese Society of Gastroenterology.
Références
Llovet JM, Bru C, Bruix J, et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.
doi: 10.1055/s-2007-1007122
Forner A, Reig M, Bruix J, et al. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.
doi: 10.1016/S0140-6736(18)30010-2
Ando E, Yamashita F, Tanaka M, et al. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer. 1997;79:1890–6.
doi: 10.1002/(SICI)1097-0142(19970515)79:10<1890::AID-CNCR8>3.0.CO;2-K
Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol. 1996;167:759–68.
doi: 10.2214/ajr.167.3.8751696
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;18(359):1734–9.
doi: 10.1016/S0140-6736(02)08649-X
Jang BK, Chung WJ, Park KS, et al. The efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma according to extrahepatic collateral feeding vessels. Korean J Hepatol. 2005;11:359–70.
pubmed: 16380665
Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer. 2005;103:2419–26.
doi: 10.1002/cncr.21043
Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990–7.
doi: 10.1002/cncr.21832
Uka K, Aikata H, Takaki S, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42:845–53.
doi: 10.1007/s00535-007-2099-8
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
doi: 10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
doi: 10.1016/S1470-2045(08)70285-7
Kim HY, Kim JD, Bae SH, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2010;16:355–61.
doi: 10.3350/kjhep.2010.16.4.355
Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010;781:148–53.
doi: 10.1159/000315244
Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56:886–92.
doi: 10.1016/j.jhep.2011.10.021
Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013;58:724–9.
doi: 10.1016/j.jhep.2012.11.009
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
doi: 10.1016/S0140-6736(16)32453-9
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.
doi: 10.1016/S0140-6736(18)30207-1
Personeni N, Rimassa L, Pressiani T, et al. Cabozantinib for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2019;19:847–55.
doi: 10.1080/14737140.2019.1674141
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–96.
doi: 10.1016/S1470-2045(18)30937-9
Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993;23:105–9.
pubmed: 8390584
Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664–71.
doi: 10.1002/ijc.23131
Tohyama O, Maysui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014: 638747.
doi: 10.1155/2014/638747
Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.
doi: 10.1186/2045-824X-6-18
Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49:111–7.
doi: 10.1111/hepr.13243
Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588–95.
doi: 10.1002/cncr.10694
Song DS, Song MJ, Bae SH, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445–54.
doi: 10.1007/s00535-014-0978-3
Kawaoka T, Aikata H, Kobayashi T, et al. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2018;48:1118–30.
doi: 10.1111/hepr.13232
Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol. 2016;27:2090–6.
doi: 10.1093/annonc/mdw323
Toya R, Murakami R, Baba Y, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84:266–71.
doi: 10.1016/j.radonc.2007.07.005
Fujino H, Kimura T, Aikata H, et al. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607–17.
doi: 10.1111/hepr.12392
Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. Oncology. 2018;94:215–22.
doi: 10.1159/000486483
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
doi: 10.1056/NEJMoa1915745
Hasegewa T, Yamakado K, Takaki H, et al. Portal venous stent placement for malignant portal venous stenosis or occlusion. Cardinovasc Intervent Radiol. 2015;38:1515–22.
doi: 10.1007/s00270-015-1123-2
Tsukamoto T, Hirohashi K, Kudo S, et al. Percutaneous transhepatic metallic stent placement for malignant portal vein stenosis. Hepatogastroenterology. 2003;50:453–5.
pubmed: 12749245
Yamakado K, Nakatsuka A, Tanaka N, et al. Malignant portal venous obstruction treated by stent placement significant factors affecting patency. J Vasc Interv Radiol. 2001;12:1407–15.
doi: 10.1016/S1051-0443(07)61699-6
Takaki H, Yamakado K, Nakatsuka A, et al. Stent placement for portal venous stenosis following major abdominal surgery. Hepatogastroenterology. 2009;56:407–10.
pubmed: 19579609
Luo JJ, Zhang ZH, Liu QX, et al. Endovascular brachytherapy combined with stent placement and transarterial chemoembolization for treatment of HCC with main portal vein tumor thrombus. Hepatol Int. 2016;10:185–95.
doi: 10.1007/s12072-015-9663-8
Lu J, Guo JH, Zhu HD, et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28:786–94.
doi: 10.1016/j.jvir.2017.02.014
Ishikawa T, Kubota T, Abe H, et al. Percutaneous transhepatic portal vein stent placement can improve prognosis for hepatocellular carcinoma patients with portal vein tumor thrombosis. Hepatogastroenterology. 2014;61:413–6.
pubmed: 24901152